You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Selective and potent COX-2 inhibitor (in vitro IC50 values are 0.005 and 140 μM for human recombinant COX-2 and COX-1 respectively). Displays potent anti-inflammatory activity in vivo.
Sold for research purposes under agreement from Pfizer Inc.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 314.36. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.18 mL||15.91 mL||31.81 mL|
|5 mM||0.64 mL||3.18 mL||6.36 mL|
|10 mM||0.32 mL||1.59 mL||3.18 mL|
|50 mM||0.06 mL||0.32 mL||0.64 mL|
References are publications that support the biological activity of the product.
Talley et al (2000) 4-[5-methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J.Med.Chem. 43 775 PMID: 10715145
Walker et al (2001) A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem.J. 357 709 PMID: 11463341
Gierse et al (2005) Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J.Pharmacol.Exp.Ther. 312 1206 PMID: 15494548
If you know of a relevant reference for Valdecoxib, please let us know.
View Related Products by Product Action
Keywords: Valdecoxib, Valdecoxib supplier, cyclooxygenase-2, COX-2, inhibitors, inhibits, selective, potent, NSAIDs, pfizer, non-steroidal, anti-inflammatory, Cyclooxygenase, 4206, Tocris Bioscience
Citations for Valdecoxib
Citations are publications that use Tocris products.
Currently there are no citations for Valdecoxib. Do you know of a great paper that uses Valdecoxib from Tocris? Please let us know.
Reviews for Valdecoxib
There are currently no reviews for this product. Be the first to review Valdecoxib and earn rewards!
Have you used Valdecoxib?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.